abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Esta página não está disponível em Português e está sendo exibida em English

Artigo

17 Ago 2006

Author:
Daniel Rosan, Program Director for Public Health, Interfaith Center on Corporate Responsibility [USA]

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

[identifies pharmaceutical best practice in key areas including research, paediatric needs, drug accessibility, reporting, philanthropy, political engagement; rates 15 top pharmaceutical firms on each practice: Abbott Laboratories, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Eli Lilly, Merck, Novartis, Pfizer, Hoffmann-La Roche (part of Roche), sanofi-aventis, Schering-Plough, Wyeth]

Linha do tempo